Aptus Pharma shareholders unanimously approved all three resolutions at its 16th Annual General Meeting held on September 14, 2026. The special resolution for the preferential allotment of equity shares passed with 100% assent, alongside the adoption of financial statements and director re-appointment.

The meeting was conducted via video conferencing and other audio-visual means in compliance with SEBI Listing Regulations and the Companies Act, 2013. A live webcast was facilitated for stakeholders unable to attend virtually.

Voting Results

The scrutinizer’s report, submitted by Company Secretary Nalin Ganatra, confirmed that all votes were cast via remote e-voting, with no dissent recorded across any shareholder category. A total of 130 members voted, representing 1,39,38,000 shares out of the total eligible shares on the record date of September 7, 2026.

Resolution-wise Breakdown

Promoter and promoter group shareholders held 1,25,00,000 shares and voted entirely in favour. Public non-institutional shareholders held 14,38,000 shares and also voted unanimously in favour. No institutional public shareholders participated in the voting process.

Attendance and Governance

Mr. Chetan Shantilal Lalseta, Chairman, presided over the meeting. The requisite quorum under Section 103 of the Act was present throughout. A total of 28 members attended the meeting via video conferencing: four from the promoter group and 24 from the public category.

Directors Present

Key managerial personnel in attendance included Ghanshyam Vinubhai Pansuriya (CEO), Kapilbhai Hasmukhbhai Chandarana (CFO), and Mohini Hardikbhai Gandhi (Company Secretary).

Audit Reports

The statutory auditors’ report on the financial statements for the year ended March 31, 2026, and the secretarial audit report contained no qualifications, reservations, adverse remarks, or disclaimers. Consequently, these reports were not read out during the meeting as per regulatory guidelines.

Remote e-voting was open from September 11, 2026, to September 13, 2026. Voting facilities remained available during the meeting and for 15 minutes after its conclusion.

Aptus Pharma Limited will host a group meeting with investors and analysts in Mumbai on September 18, 2026. The session is scheduled from 4:00 pm to 6:00 pm.

The company issued the intimation on September 12, 2026, pursuant to Regulation 30 (6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management will conduct the interaction based strictly on publicly available information.

Meeting Details

Tejash Hathi, Managing Director of Aptus Pharma Limited, signed the disclosure. The company noted that changes to the schedule may occur due to exigencies on the part of participants or the company.